CD79A and acute myeloid leukemia: For example, S16 in IGHV4-59 of AML-Igα (88/106, 83.0%) had a higher mutation frequency than that of B-Igα (63/315, 20.0%) (Figure 5C), but S92 in IGHV4-59 of AML-Igα (19/106, 17.9%) had a lower mutation frequency than that of B-Igα (268/315, 85.1%) in AML9 (Figure 5D).